Amarin Corporation plc (AMRN) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Amarin Corporation (AMRN) by buying shares or fractional shares at any major US broker, where it trades as American Depositary Shares on the Nasdaq. Amarin is a pharmaceutical company built almost entirely around a single product: VASCEPA (icosapent ethyl), a purified fish-oil-derived prescription therapy that lowers triglycerides and, based on its cardiovascular outcomes data, is used to reduce cardiovascular risk in certain statin-treated patients. The single biggest thing to understand is that US generic competition has already sharply eroded VASCEPA's domestic sales, so the current story centers on stabilizing the US business, growing internationally through partners like Recordati in Europe, and running the company lean enough to generate cash despite the generic pressure.
AMRN stock price
As of 2026-07-14, Amarin Corporation plc (AMRN) last closed at $14.62, down 9.2% over the past year. Over the past 52 weeks it has traded between $13.50 and $20.25.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Amarin Corporation plc's investor relations page. Walnut is informational, not investment advice.
What does Amarin Corporation plc (AMRN) do?
Amarin Corporation is a pharmaceutical company whose business is dominated by one product, VASCEPA (marketed as VAZKEPA in Europe), the brand name for icosapent ethyl, a highly purified omega-3 prescription therapy derived from fish oil. VASCEPA lowers triglycerides and, based on a cardiovascular outcomes trial, is used to reduce the risk of cardiovascular events in certain statin-treated patients with elevated triglycerides. Amarin makes money by selling VASCEPA in the United States and by licensing and collecting royalties from partners who commercialize the drug in other regions. Because the company depends so heavily on a single molecule, its fortunes track VASCEPA's prescription volumes, pricing, and competitive dynamics rather than a diversified portfolio.
The defining feature of the investment picture is that US generic versions of icosapent ethyl have launched and taken meaningful share, which sharply reduced Amarin's domestic revenue from its earlier peak and reshaped the company into a leaner operation. In 2026 the company has emphasized cost reduction, positive cash flow, and a refined global business model adopted in mid-2025. It reported growth in VASCEPA-branded prescriptions in early 2026 and pointed to updated US lipid guidelines that support icosapent ethyl's role, while its European partner Recordati has been launching VAZKEPA across additional countries. Amarin also carries a substantial cash balance and no significant debt, giving it a cushion, but its long-term value depends on whether international growth and a stabilized US base can offset the generic erosion at home.
What's driving Amarin Corporation plc (AMRN)?
1. Stabilizing the US VASCEPA franchise
After generic icosapent ethyl launched, Amarin's US revenue fell well below its former peak, so a central goal is stabilizing what remains of the branded business. The company has reported growth in VASCEPA-branded prescriptions in early 2026 and expects volumes to stay relatively stable through the year. Defending the branded share against cheaper generics, while running a leaner commercial operation, is now a core part of the story rather than aggressive US growth.
2. International expansion through partners
Outside the US, Amarin relies on partners to commercialize the drug, most notably Recordati, which has been launching VAZKEPA across European markets. International licensing and royalty income is one of the few genuine growth avenues left, since Europe and other regions are earlier in adoption and less exposed to US generic dynamics. The pace of partner launches and reimbursement decisions abroad is a key swing factor for future revenue.
3. Cost discipline and cash generation
Amarin has cut operating expenses substantially and shifted toward a leaner model, narrowing its losses and reporting positive cash flow in consecutive quarters in early 2026, with a stated goal of full-year positive cash flow. For a company facing revenue erosion, disciplined spending and preserving its large cash balance are as important to shareholder value as top-line trends. The market watches whether it can stay cash-generative without a growth engine.
4. Clinical guidelines and scientific positioning
Amarin points to updated US lipid guidelines and cardiovascular outcomes data as support for icosapent ethyl's role in reducing risk in statin-treated patients with elevated triglycerides. Favorable guideline language can reinforce prescribing, though it benefits generics too, since they share the same molecule. The scientific case for the drug is a differentiator relative to plain fish oil, but it does not by itself protect Amarin's branded pricing from generic competition.
What are the risks to Amarin Corporation plc (AMRN)?
The overriding risk is single-product concentration: Amarin's fortunes rest almost entirely on VASCEPA, so any pressure on that franchise flows straight to the company. US generic competition has already taken significant share and continues to cap domestic pricing and volume, limiting growth at home. International success depends on partners like Recordati executing launches and securing reimbursement, which Amarin does not fully control. Years of patent litigation and prior court rulings that invalidated key US patents underscore how exposed the branded product is. The company has been through management and strategy changes as it adapted to the generic era, adding execution uncertainty. While a large cash balance and minimal debt provide a cushion, a one-product company with eroding US sales has limited catalysts, and the stock can be volatile around prescription trends, guideline updates, and any strategic or partnership news.
How is Amarin Corporation plc (AMRN) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amarin Corporation plc's investor relations page or your broker.
- Total net revenue (Q1 2026): ~$45 million reported, up modestly year over year per the company (verify live)
- Revenue mix: Mostly US VASCEPA product sales plus growing licensing and royalty income from international partners
- Profitability: Operating and net losses reported in Q1 2026 but narrowing sharply as costs were cut
- Cash flow: Company reported positive cash flow in consecutive quarters and targets full-year 2026 positive cash flow
- Cash position: Substantial cash balance (roughly $300 million reported at end of Q1 2026) with minimal debt; confirm current figure
- Market cap: Small-cap; verify the live figure, as the stock has been volatile since the generic erosion
These figures are approximate, tied to the asOf date, and should be verified against Amarin's latest filings before acting. For a company in revenue transition, headline multiples are less meaningful than the trajectory of US branded volumes, international royalty growth, and cash generation. A large cash balance relative to market value is part of the value case, but cash can be consumed if the business does not stabilize, so watch the cash-flow trend rather than any single quarter.
Who competes with Amarin Corporation plc (AMRN)?
Generic icosapent ethyl manufacturers
The most direct competition comes from generic versions of icosapent ethyl, from companies such as Hikma (Roxane), Dr. Reddy's, Teva, and Apotex, which have launched cheaper copies of VASCEPA in the US. Because they sell the same molecule, generics compete primarily on price and have taken substantial share, which is the central pressure on Amarin's US revenue.
Other lipid and cardiovascular therapies
VASCEPA competes for prescribing attention within the broader lipid-management and cardiovascular-risk space, which includes statins, other triglyceride-lowering approaches, and newer cardiometabolic therapies from large pharmaceutical companies. These are not identical products, but they compete for the same physicians and patients managing cardiovascular risk, and evolving treatment guidelines shape where each fits.
Over-the-counter fish oil and omega-3 products
Non-prescription fish oil and omega-3 supplements are a looser form of competition. They are not equivalent to prescription-grade, purified icosapent ethyl and lack the same clinical evidence, but some patients and prescribers view them as substitutes on cost grounds, which can blur the market and complicate Amarin's messaging about the branded product's distinct clinical profile.
How to invest in Amarin Corporation plc (AMRN)
There are three common ways to get AMRN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AMRN sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where AMRN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Amarin Corporation plc (AMRN)
Amarin is a one-product company whose US franchise has been hit hard by generic competition, so the thesis now rests on cost discipline, positive cash flow, and international expansion of VASCEPA through partners. It offers a large cash cushion and a guideline-supported drug, but limited growth catalysts and heavy single-product concentration.
Build a basket around AMRN with Walnut
Use Amarin Corporation plc as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AMRN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The case for Amarin is a large cash balance, a guideline-supported drug, cost discipline, positive cash flow, and international growth potential through partners. The case against is heavy single-product concentration, US revenue eroded by generics, and limited growth catalysts. Weigh the cash cushion against the lack of a clear growth engine before deciding.
What does Amarin actually do?
+
Amarin is a pharmaceutical company built around one product, VASCEPA (icosapent ethyl), a purified prescription omega-3 therapy that lowers triglycerides and is used to reduce cardiovascular risk in certain statin-treated patients. It sells the drug in the US and earns licensing and royalty income from partners who commercialize it, as VAZKEPA, in other regions such as Europe.
Why did Amarin's revenue fall so much?
+
Generic versions of icosapent ethyl launched in the US after courts invalidated key VASCEPA patents, and those cheaper copies took significant market share. Because Amarin depends almost entirely on this one product, the generic competition sharply reduced its US revenue from its earlier peak and forced the company to cut costs and refocus on international growth and cash generation.
Is Amarin profitable?
+
As of early 2026 Amarin was still reporting net losses, but they had narrowed substantially after deep cost cuts, and the company reported positive cash flow in consecutive quarters with a goal of full-year 2026 positive cash flow. So the trend was toward financial stabilization even though it was not consistently net-income positive. Verify the latest quarterly results before relying on any figure.
What is VASCEPA and how is it different from fish oil?
+
VASCEPA is the brand name for icosapent ethyl, a highly purified, single-molecule prescription omega-3 therapy, not a dietary supplement. It is backed by a cardiovascular outcomes trial and is included in treatment guidance for reducing cardiovascular risk in certain statin-treated patients with elevated triglycerides. That clinical evidence distinguishes it from over-the-counter fish oil, though generics of the same molecule now compete on price.
Does Amarin pay a dividend?
+
No. Amarin does not pay a dividend. As a company managing through revenue erosion and focused on cost discipline and cash preservation, it retains its capital rather than returning it to shareholders. Investors in the stock are generally looking at its cash balance and potential business stabilization or international growth, not income.
How is Amarin growing internationally?
+
Outside the US, Amarin relies on partners to commercialize the drug. Its European partner Recordati has been launching VAZKEPA across multiple countries, including markets in Europe, and plans further expansion over time. International licensing and royalty income is one of Amarin's main growth avenues, since those markets are earlier in adoption and less exposed to US generic competition.
How can I get exposure to Amarin through an ETF?
+
As a small-cap ADS, AMRN may appear in some small-cap, biotech, or pharmaceutical index funds, typically at a small weighting. ETF exposure spreads single-stock risk but means any Amarin move affects you only slightly. Always check a fund's holdings and weightings before assuming it gives you meaningful exposure to Amarin specifically.
What are the main risks of investing in AMRN?
+
The biggest risk is single-product concentration: everything depends on VASCEPA, whose US sales have been eroded by generics that continue to cap pricing and volume. International growth hinges on partners Amarin does not fully control, and the company has limited growth catalysts. Although it holds substantial cash and little debt, a one-product company in revenue transition can be volatile and offers an uncertain long-term path.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Amarin Corporation plc's investor relations page or your broker before making investment decisions.